網膜生物製剤の世界市場レポート 2025年

網膜生物製剤市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR11.9%で445億1,000万米ドルに成長します。予測期間の成長は、治療用途の拡大、個別化医療、新興市場の成長、生物製剤の強力なパイプライン、共同研究やパートナーシップ、政府の取り組みや支援に起因すると考えられます。予測期間における主な動向には、非侵襲的な投与方法、実臨床エビデンスの活用、適応症の拡大、規制経路の合理化、患者中心のアウトカムなどがあります。

糖尿病性眼疾患の罹患率の上昇が、今後数年間の網膜生物製剤市場の成長を牽引すると予想されます。糖尿病性眼疾患は、糖尿病に起因する合併症であり、この疾患を持つ人の視力低下や失明につながる可能性があります。網膜生物製剤は、よりターゲットを絞った効果的な治療オプションの可能性を提供し、糖尿病性眼疾患に関連する視力低下を予防するための早期介入とより良い結果を可能にします。例えば、2023年12月にオーストラリアの政府機関であるオーストラリア統計局が発表したデータによると、2022年にはオーストラリア人口の5.3％（約130万人）が糖尿病を患っており、3.3％から大幅に増加しています。このように、糖尿病性眼疾患の有病率の増加が網膜生物製剤市場の拡大に拍車をかけています。

個別化医療に対する需要の高まりが、網膜生物製剤市場の拡大に拍車をかけると予測されています。個別化医療は、個人のユニークな遺伝子構成に合わせて、より効果的で正確なヘルスケア介入を提供します。網膜生物製剤の領域では、個人の遺伝子や分子プロファイルに基づいて治療アプローチをカスタマイズし、副作用を最小限に抑えながら有効性を最適化する個別化医療戦略が採用されています。2023年1月に個別化医療連合が発表したデータによると、2022年に米食品医薬品局（FDA）の医薬品評価研究センター（CDER）が承認した37の新規分子化合物（NME）のうち、約34％（12NME）が個別化医療連合によって個別化医療に分類されています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界網膜生物製剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の網膜生物製剤市場：成長率分析
• 世界の網膜生物製剤市場の実績：規模と成長, 2019-2024
• 世界の網膜生物製剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界網膜生物製剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の網膜生物製剤市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血管内皮増殖因子（VEGF）-A拮抗薬
• 腫瘍壊死因子（TNF）-A阻害剤
• 世界の網膜生物製剤市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 黄斑変性症
• 糖尿病網膜症
• ぶどう膜炎
• 糖尿病黄斑浮腫
• その他の適応症
• 世界の網膜生物製剤市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 薬局
• 専門クリニック
• オンライン薬局
• その他の流通チャネル
• 世界の網膜生物製剤市場血管内皮増殖因子（VEGF）-A拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 低分子阻害剤
• 世界の網膜生物製剤市場、腫瘍壊死因子（TNF）-A阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 融合タンパク質

第7章 地域別・国別分析

• 世界の網膜生物製剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の網膜生物製剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 網膜生物製剤市場：競合情勢
• 網膜生物製剤市場：企業プロファイル
  • Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • MeiraGTx Limited Overview, Products and Services, Strategy and Financial Analysis
  • Oxurion NV Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Amgen Inc.
• Spark Therapeutics Inc.
• Bayer AG
• Bausch Health Companies Inc.
• Merck & Co. Inc.
• Santen Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Boehringer Ingelheim
• Eyenovia Inc.
• EyePoint Pharmaceuticals Inc.
• Iveric Bio Inc.
• Kodiak Sciences Inc.
• Aerie Pharmaceuticals Inc.
• Alimera Sciences Inc.
• Ocular Therapeutix Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 網膜生物製剤市場2029：新たな機会を提供する国
• 網膜生物製剤市場2029：新たな機会を提供するセグメント
• 網膜生物製剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Retinal biologics refer to bioengineered macromolecules that are implanted inside the eyes to treat chronic retinal diseases. These highly precise compounds target inflammatory mediators and are used in the treatment of various inflammatory, corneal, and retinal medical conditions.

The main types of retinal biologics include vascular endothelial growth factor (VEGF)-A antagonists and tumor necrosis factor (TNF)-A inhibitors. A VEGF-A antagonist is a substance that inhibits the activity of vascular endothelial growth factor, a potent angiogenic factor and an essential growth factor for vascular endothelial cells. These biologics are administered for various indications, including macular degeneration, diabetic retinopathy, uveitis, diabetic macular edema, and others. They are typically available in hospitals, pharmacies, specialty clinics, online pharmacies, and other healthcare facilities.

The retinal biologics market research report is one of a series of new reports from The Business Research Company that provides retinal biologics market statistics, including retinal biologics industry global market size, regional shares, competitors with a retinal biologics market share, detailed retinal biologics market segments, market trends, and opportunities, and any further data you may need to thrive in the retinal biologics industry. This retinal biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The retinal biologics market size has grown rapidly in recent years. It will grow from $25.17 billion in 2024 to $28.42 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increased incidence of retinal disorders, aging population, rising awareness and early diagnosis, evolving healthcare infrastructure, and increasing healthcare expenditure

The retinal biologics market size is expected to see rapid growth in the next few years. It will grow to $44.51 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to expanding therapeutic applications, personalized medicine, emerging market growth, a strong pipeline of biologics, collaborations and partnerships, government initiatives and support. Major trends in the forecast period include non-invasive delivery methods, real-world evidence utilization, expanded indications, regulatory pathway streamlining, and patient-centric outcomes.

The rising incidence of diabetic eye disease is anticipated to drive the growth of the retinal biologics market in the coming years. Diabetic eye disease is a complication arising from diabetes that can lead to vision loss and blindness among individuals with the condition. Retinal biologics offer the potential for more targeted and effective treatment options, enabling earlier intervention and better outcomes in preventing vision loss related to diabetic eye disease. For example, in December 2023, data from the Australian Bureau of Statistics, a government agency in Australia, indicated that in 2022, 5.3% of the Australian population (approximately 1.3 million people) had diabetes, which represents a significant increase from 3.3%. Thus, the growing prevalence of diabetic eye disease is fueling the expansion of the retinal biologics market.

The growing demand for personalized medicine is anticipated to fuel the expansion of the retinal biologics market. Personalized medicine, tailored to an individual's unique genetic makeup, offers more effective and precise healthcare interventions. In the realm of retinal biologics, personalized medicine strategies are employed to customize treatment approaches based on individual genetic and molecular profiles, optimizing efficacy while minimizing adverse effects. Data from the Personalized Medicine Coalition in January 2023 revealed that out of the 37 new molecular entities (NMEs) approved by the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) in 2022, approximately 34% (12 NMEs) are classified as personalized medicines by the Personalized Medicine Coalition.

A prominent trend gaining traction in the retinal biologics market is product innovation. Leading companies in this market are actively engaged in the development of innovative products to enhance their market position and gain a competitive edge. Notably, F. Hoffmann-La Roche Ltd., a Switzerland-based healthcare company, announced in May 2023 that the U.S. Food and Drug Administration had accepted the company's supplemental biologics license application (sBLA) for Vabysmo (faricimab), designed for the treatment of macular edema following retinal vein occlusion (RVO). Vabysmo is a bispecific antibody that has demonstrated early and persistent visual improvement, achieving the primary endpoint of non-inferiority to aflibercept. This product marks a significant advancement as the first bispecific antibody approved for the eye to treat 'wet' age-related macular degeneration and diabetic macular edema.

Strategic partnerships are a prominent approach adopted by major companies in the retinal biologics market to fortify their market presence and offer innovative solutions. Biogen Inc., a U.S.-based biotechnology company, entered into a strategic partnership with Samsung Bioepis Co., Ltd., a South Korean biotechnology company, in June 2022. This collaboration led to the launch of BYOOVIZ, a biosimilar for retinal vascular disorders. BYOOVIZ holds potential for substantial cost savings within the U.S. healthcare system while expanding access for patients with retinal disorders.

In January 2023, Coherus BioSciences Inc., a U.S.-based biosimilar therapeutics company, secured exclusive commercialization rights to FYB203, a biosimilar candidate of Eylea (aflibercept), from Klinge Biopharma GmbH in the United States. This strategic acquisition expands Coherus' market opportunity in the anti-VEGF medications segment, supporting mid-to-long-term growth and revenue potential. Klinge Biopharma GmbH is a Germany-based firm specializing in anti-VEGF medications.

Major companies operating in the retinal biologics market include Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis AG, Amgen Inc., Spark Therapeutics Inc., Bayer AG, Bausch Health Companies Inc., Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Boehringer Ingelheim, Eyenovia Inc., EyePoint Pharmaceuticals Inc., Iveric Bio Inc., Kodiak Sciences Inc., Aerie Pharmaceuticals Inc., Alimera Sciences Inc., Ocular Therapeutix Inc., Acucela Inc., Clearside Biomedical Inc., Ophthotech Corporation, Xcovery Holdings, Athenex Inc., Fidia Farmaceutici S.p.A, Eton Pharmaceuticals Inc.

North America was the largest region in the retinal biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinal biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinal biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The retinal biologics market consists of sales of ranibizumab, aflibercept, and brolucizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Retinal Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinal biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for retinal biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The retinal biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Vascular Endothelial Growth Factor (VEGF)-A Antagonist; Tumor Necrosis Factor (TNF)-A Inhibitor
• 2) By Indication: Macular Degeneration; Diabetic Retinopathy; Uveitis; Diabetic Macular Edema; Other Indications
• 3) By Distribution Channel: Hospitals; Pharmacies; Specialty Clinics; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Vascular Endothelial Growth Factor (VEGF)-A Antagonist: Monoclonal Antibodies; Small Molecule Inhibitors
• 2) By Tumor Necrosis Factor (TNF)-A Inhibitor: Monoclonal Antibodies; Fusion Proteins
• Companies Mentioned: Regeneron Pharmaceuticals Inc.; AbbVie Inc.; MeiraGTx Limited; Oxurion NV; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Retinal Biologics Market Characteristics

3. Retinal Biologics Market Trends And Strategies

4. Retinal Biologics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Retinal Biologics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Retinal Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Retinal Biologics Market Growth Rate Analysis
• 5.4. Global Retinal Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Retinal Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Retinal Biologics Total Addressable Market (TAM)

6. Retinal Biologics Market Segmentation

• 6.1. Global Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vascular Endothelial Growth Factor (VEGF)-A Antagonist
• Tumor Necrosis Factor (TNF)-A Inhibitor
• 6.2. Global Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Macular Degeneration
• Diabetic Retinopathy
• Uveitis
• Diabetic Macular Edema
• Other Indications
• 6.3. Global Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Pharmacies
• Specialty Clinics
• Online Pharmacies
• Other Distribution Channels
• 6.4. Global Retinal Biologics Market, Sub-Segmentation Of Vascular Endothelial Growth Factor (VEGF)-A Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Small Molecule Inhibitors
• 6.5. Global Retinal Biologics Market, Sub-Segmentation Of Tumor Necrosis Factor (TNF)-A Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Fusion Proteins

7. Retinal Biologics Market Regional And Country Analysis

• 7.1. Global Retinal Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Retinal Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Retinal Biologics Market

• 8.1. Asia-Pacific Retinal Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Retinal Biologics Market

• 9.1. China Retinal Biologics Market Overview
• 9.2. China Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Retinal Biologics Market

• 10.1. India Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Retinal Biologics Market

• 11.1. Japan Retinal Biologics Market Overview
• 11.2. Japan Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Retinal Biologics Market

• 12.1. Australia Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Retinal Biologics Market

• 13.1. Indonesia Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Retinal Biologics Market

• 14.1. South Korea Retinal Biologics Market Overview
• 14.2. South Korea Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Retinal Biologics Market

• 15.1. Western Europe Retinal Biologics Market Overview
• 15.2. Western Europe Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Retinal Biologics Market

• 16.1. UK Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Retinal Biologics Market

• 17.1. Germany Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Retinal Biologics Market

• 18.1. France Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Retinal Biologics Market

• 19.1. Italy Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Retinal Biologics Market

• 20.1. Spain Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Retinal Biologics Market

• 21.1. Eastern Europe Retinal Biologics Market Overview
• 21.2. Eastern Europe Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Retinal Biologics Market

• 22.1. Russia Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Retinal Biologics Market

• 23.1. North America Retinal Biologics Market Overview
• 23.2. North America Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Retinal Biologics Market

• 24.1. USA Retinal Biologics Market Overview
• 24.2. USA Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Retinal Biologics Market

• 25.1. Canada Retinal Biologics Market Overview
• 25.2. Canada Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Retinal Biologics Market

• 26.1. South America Retinal Biologics Market Overview
• 26.2. South America Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Retinal Biologics Market

• 27.1. Brazil Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Retinal Biologics Market

• 28.1. Middle East Retinal Biologics Market Overview
• 28.2. Middle East Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Retinal Biologics Market

• 29.1. Africa Retinal Biologics Market Overview
• 29.2. Africa Retinal Biologics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Retinal Biologics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Retinal Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Retinal Biologics Market Competitive Landscape And Company Profiles

• 30.1. Retinal Biologics Market Competitive Landscape
• 30.2. Retinal Biologics Market Company Profiles
  • 30.2.1. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. MeiraGTx Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Oxurion NV Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Retinal Biologics Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. Spark Therapeutics Inc.
• 31.3. Bayer AG
• 31.4. Bausch Health Companies Inc.
• 31.5. Merck & Co. Inc.
• 31.6. Santen Pharmaceutical Co. Ltd.
• 31.7. Pfizer Inc.
• 31.8. Boehringer Ingelheim
• 31.9. Eyenovia Inc.
• 31.10. EyePoint Pharmaceuticals Inc.
• 31.11. Iveric Bio Inc.
• 31.12. Kodiak Sciences Inc.
• 31.13. Aerie Pharmaceuticals Inc.
• 31.14. Alimera Sciences Inc.
• 31.15. Ocular Therapeutix Inc.

32. Global Retinal Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Retinal Biologics Market

34. Recent Developments In The Retinal Biologics Market

35. Retinal Biologics Market High Potential Countries, Segments and Strategies

• 35.1 Retinal Biologics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Retinal Biologics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Retinal Biologics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer